Overview

BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Status:
Completed
Trial end date:
2007-05-31
Target enrollment:
Participant gender:
Summary
This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Pioglitazone
Rosiglitazone